Vascular Occlusion Enables Selecting Acute Ischemic Stroke Patients for Treatment With Desmoteplase | Zendy

Jochen B. Fiebach | Zendy; Yasir AlRawi | Zendy; Max Wintermark | Zendy; Anthony J. Furlan | Zendy; Howard A. Rowley | Zendy; Annika Lindstén | Zendy; Jamal Smyej | Zendy; Paul Eng | Zendy; Steven Warach | Zendy; Salvador Pedraza | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Vascular Occlusion Enables Selecting Acute Ischemic Stroke Patients for Treatment With Desmoteplase

Author(s) -

Jochen B. Fiebach,

Yasir AlRawi,

Max Wintermark,

Anthony J. Furlan,

Howard A. Rowley,

Annika Lindstén,

Jamal Smyej,

Paul Eng,

Steven Warach,

Salvador Pedraza

Publication year - 2012

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.111.642322

Subject(s) - medicine , stroke (engine) , occlusion , ischemic stroke , vascular occlusion , vascular disease , endovascular treatment , cardiology , acute stroke , ischemia , surgery , tissue plasminogen activator , aneurysm , engineering , mechanical engineering

Desmoteplase is a novel and highly fibrin-specific thrombolytic agent. Evidence of safety and efficacy was obtained in 2 phase II trials (Desmoteplase In Acute Ischemic Stroke [DIAS] and Desmoteplase for Acute Ischemic Stroke [DEDAS]). The DIAS-2 phase III trial did not replicate the positive phase II efficacy findings. Post hoc analyses were performed with the aim of predicting treatment responders based on CTA and MRA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research